Independent scientific consulting

Senior scientists.
Direct engagement.

ISO/IEC 17025 lab accreditation readiness, GMP and cGMP compliance, analytical method validation, microbiology, expert witness, and Federal Pathway / Schedule III advisory — across cannabis, hemp, food & beverage, pharmaceutical, and dietary-supplement industries.

Why this firm exists

Most consulting firms grow by hiring junior staff under senior partners. The partners sell the engagement; the juniors execute it. By the time the work lands on a bench, the senior name that won the deal is two or three calls removed.

Intrepid Scientific exists to invert that model.

We are four principals — three PhDs and a pharmaceutical-trained quality professional — each with an established consulting practice and a public reputation in our fields. We chose each other after years of collaborating on shared engagements and expert-witness matters. We are now consolidating that work into a single firm so clients can engage four senior specialists under one contract, with one point of accountability, and no junior backfill.

The names on the wall deliver the work. Andrew runs the project. Kate, Julie, and Tess work the bench, the audit, or the deposition themselves. There is no junior associate inserted after the sale.

Cofounders

Vetted alignment, not assembled team. We picked each other.

Andrew Samann

B.S. Biochemistry (U-M)

GMP, regulatory, QMS. Leads ASTM D37.02 QMS Subcommittee for Cannabis. 100+ engagements across NA, SA, EU.

Kate Evans, PhD

Ph.D., analytical chemistry + microbiology

ANAB and A2LA lead assessor (ISO/IEC 17025). Technical Contact, ASTM D8493-23. Pharma analysis + cGMP.

Tess Eidem, PhD

Ph.D., Microbiology · PCQI

Cannabis bioaerosols, environmental monitoring, microbiology QC. Senior Research Associate, CU Boulder.

Julie Kowalski, PhD

Ph.D., Analytical Chemistry

Chairs AOAC CASP Pesticide Think Tank. Past President NACRW. GC/LC method development and validation.

Time-sensitive — federal cannabis Schedule III

The 60-Day Federal Pathway

On April 28, 2026, AG Order 6754-2026 placed FDA-approved and state-medical marijuana in Schedule III and opened a 60-day expedited DEA registration window. The window closes on or about June 27, 2026.

We’ve written a step-by-step transition primer for state-licensed cultivators applying under 21 CFR § 1301.13(k) — eligibility, document pack, application mechanics, public-interest defense, the Single Convention buy/sell-back, and a complete pre-submission checklist.

Talk to us

Send a note. Tell us a little about what you’re working on. We reply directly, from a senior member of the firm.